EyePoint Pharmaceuticals announced the commercial launch of Yutiq, an intravitreal implant containing fluocinolone acetonide, in the United States.
According to a company press release, the micro-insert is now available for ordering and delivery. Yutiq is FDA approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
“We are pleased to announce the availability of Yutiq in the U.S., which is an advancement in the treatment of chronic noninfectious posterior segment uveitis,” Nancy Lurker, president and CEO of EyePoint, said in the
Uncategorized